Table 2

Health outcomes among HCV patients and controls
HCV group Unmatched controls Matched controls
(n = 286) (n = 56,880) (n = 286)
Mean SD Mean SD p-value* Mean SD p-value†
Work impairment
 Absenteeism 7.78% 19.16% 5.44% 19.20% <.001 5.45% 20.34% .010
 Presenteeism 26.27% 27.58% 15.83% 22.79% <.001 14.45% 21.58% <.001
 Overall work impairment 30.45% 31.42% 19.39% 27.70% <.001 18.30% 27.47% <.001
Activity impairment 34.37% 30.60% 24.38% 28.16% <.001 28.46% 30.57% .011
Healthcare use
 Annual physician visits 19.80 23.93 10.66 14.64 <.001 13.26 19.21 <.001
 Annual ER visits 0.68 2.11 0.38 1.90 .006 0.39 1.19 .330
 Annual hospitalizations 0.52 1.59 0.26 2.14 <.001 0.27 0.98 .073
Quality of life (SF-12v2)
 MCS 44.17 9.85 46.58 10.59 <.001 46.36 10.79 .012
 PCS 43.61 10.14 48.67 9.75 <.001 46.09 10.33 .004
 Health utility 0.67 0.12 0.73 0.13 <.001 0.71 0.15 .001

Comparisons of work impairment include only the employed subsamples: 138 HCV patients, 32,179 non-HCV, and 134 matched controls.

*Indicates the significance comparing the HCV group with the unmatched control group.

†Indicates the significance comparing the HCV group with the matched control group.

Vietri et al.

Vietri et al. BMC Gastroenterology 2013 13:16   doi:10.1186/1471-230X-13-16

Open Data